Compare EPAC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPAC | EVO |
|---|---|---|
| Founded | 1910 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | EPAC | EVO |
|---|---|---|
| Price | $40.31 | $3.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $50.50 | $7.00 |
| AVG Volume (30 Days) | ★ 568.6K | 269.8K |
| Earning Date | 12-17-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | ★ 0.98 | N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | $615,911,000.00 | ★ $887,396,457.00 |
| Revenue This Year | $5.17 | N/A |
| Revenue Next Year | $5.97 | $8.80 |
| P/E Ratio | $23.99 | ★ N/A |
| Revenue Growth | ★ 3.91 | N/A |
| 52 Week Low | $35.01 | $2.84 |
| 52 Week High | $47.47 | $5.10 |
| Indicator | EPAC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 57.23 | 49.11 |
| Support Level | $35.01 | $2.87 |
| Resistance Level | $41.73 | $3.05 |
| Average True Range (ATR) | 1.36 | 0.10 |
| MACD | 0.22 | 0.03 |
| Stochastic Oscillator | 78.35 | 64.86 |
Enerpac Tool Group Corp provides high-precision hydraulic and mechanical tools, controlled-force products, and heavy lifting solutions. Operating mainly through its Industrial Tools & Services (IT&S) segment, the company designs, manufactures, and distributes branded tools, and offers maintenance, bolting, machining, joint integrity, and equipment rental services across industries such as oil & gas, manufacturing, power generation, and infrastructure. Its key products include hydraulic cylinders, pumps, torque wrenches, and bolt tensioners under the brands ENERPAC and HYDRATIGHT. The company serves customers internationally, with operations in the USA, Australia, Brazil, Germany, Saudi Arabia, the United Kingdom, and other countries, deriving the majority of its revenue from the USA.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.